菲诺利单抗注射液 | China Drugs ListFinotonlimab injection | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- 神州细胞工程有限公司Sinocelltech Ltd.
- 药品类型
- 生物药Biologic
- 治疗领域
- 肿瘤科Oncology
- 公开来源记录的适应症
- 头颈部鳞状细胞癌:本品与含铂化疗联合用于复发性和 / 或转移性头颈部鳞状细胞癌的一线治疗。 肝细胞癌:本品联合贝伐珠单抗用于既往未接受过系统治疗的不可切除或转移性肝细胞癌的患者。Head and neck squamous cell carcinoma: with platinum-based chemotherapy as first-line treatment of recurrent and/or metastatic disease. Hepatocellular carcinoma: with bevacizumab for unresectable or metastatic disease without previous systemic treatment.
- 适应症来源与口径
- 来源日期： 2025. 适应症转录自国家医保局公开的企业申报资料；不代表已核实完整的现行说明书。 新增适应症可能由较新的公告或申报资料支持，而非旧版完整说明书；请查看适应症来源。Source date(s): 2025. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label. Additional indications may be supported by newer announcements or submissions rather than the older full label; see the indication sources.
- 说明书信息局限
- 适应症已与官方公开申报资料核对。尚未取得完整原始说明书。Indications checked against an official public submission. The full original prescribing information is still unavailable.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 已纳入国家医保（乙类）Included in national insurance (Category B)
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 限：1.复发性和/或转移性头颈部鳞状细胞癌的一线治疗；2.联合贝伐珠单抗用于既往未接受过系统治疗的不可切除或转移性肝细胞癌的患者。Restricted to: (1) first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma; (2) use with bevacizumab for unresectable or metastatic hepatocellular carcinoma without previous systemic treatment.
- 医保期限
- 2026-01-01 至 2027-12-312026-01-01 to 2027-12-31
- 医保核查说明
- 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.